SG11202012222TA - New heterocyclic compounds as monoacylglycerol lipase inhibitors - Google Patents
New heterocyclic compounds as monoacylglycerol lipase inhibitorsInfo
- Publication number
- SG11202012222TA SG11202012222TA SG11202012222TA SG11202012222TA SG11202012222TA SG 11202012222T A SG11202012222T A SG 11202012222TA SG 11202012222T A SG11202012222T A SG 11202012222TA SG 11202012222T A SG11202012222T A SG 11202012222TA SG 11202012222T A SG11202012222T A SG 11202012222TA
- Authority
- SG
- Singapore
- Prior art keywords
- heterocyclic compounds
- lipase inhibitors
- new heterocyclic
- monoacylglycerol lipase
- monoacylglycerol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18188679 | 2018-08-13 | ||
| PCT/EP2019/071522 WO2020035425A1 (fr) | 2018-08-13 | 2019-08-12 | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012222TA true SG11202012222TA (en) | 2021-01-28 |
Family
ID=63244466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012222TA SG11202012222TA (en) | 2018-08-13 | 2019-08-12 | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20210277020A1 (fr) |
| EP (1) | EP3837264A1 (fr) |
| JP (1) | JP2021533093A (fr) |
| KR (1) | KR20210044217A (fr) |
| CN (1) | CN112469724A (fr) |
| AR (1) | AR115949A1 (fr) |
| AU (1) | AU2019322161A1 (fr) |
| BR (1) | BR112020025642A2 (fr) |
| CA (1) | CA3098272A1 (fr) |
| CL (1) | CL2021000361A1 (fr) |
| CR (1) | CR20210056A (fr) |
| IL (1) | IL280762A (fr) |
| MA (1) | MA53220A (fr) |
| MX (1) | MX2020013719A (fr) |
| PE (1) | PE20211380A1 (fr) |
| PH (1) | PH12021500015A1 (fr) |
| SG (1) | SG11202012222TA (fr) |
| TW (1) | TWI814882B (fr) |
| WO (1) | WO2020035425A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| WO2019105915A1 (fr) | 2017-11-28 | 2019-06-06 | F. Hoffmann-La Roche Ag | Nouveaux composés hétérocycliques |
| TW201938164A (zh) | 2018-01-08 | 2019-10-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎雜環化合物 |
| AU2019227607C1 (en) | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| JP7391046B2 (ja) | 2018-05-18 | 2023-12-04 | インサイト・コーポレイション | Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体 |
| PE20211089A1 (es) | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| BR112022002375A2 (pt) * | 2019-09-12 | 2022-07-19 | Hoffmann La Roche | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl |
| WO2021048241A1 (fr) * | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | Composés radiomarqués |
| JP2022549810A (ja) * | 2019-09-23 | 2022-11-29 | エフ．ホフマン－ラ ロシュ アーゲー | 複素環化合物 |
| WO2021058445A1 (fr) * | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | Nouveaux inhibiteurs hétérocycliques de la monoacylglycérol lipase (magl) |
| BR112022003357A2 (pt) * | 2019-09-24 | 2022-05-17 | Hoffmann La Roche | Compostos heterocíclicos |
| MX2023002224A (es) | 2020-09-03 | 2023-03-15 | Hoffmann La Roche | Compuestos heterociclicos. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| MX2012002641A (es) | 2009-09-10 | 2012-03-14 | Hoffmann La Roche | Inhibidores de cinasa janus (jak). |
| WO2011059118A1 (fr) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | Système de test de perception olfactive |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| TW201326180A (zh) * | 2011-11-30 | 2013-07-01 | Actelion Pharmaceuticals Ltd | ３，７－二取代八氫－２Ｈ－吡啶并［４，３－ｅ］［１，３］□嗪－２－酮抗生素 |
| WO2016158956A1 (fr) * | 2015-03-30 | 2016-10-06 | 武田薬品工業株式会社 | Composé hétérocyclique |
| US10407407B2 (en) | 2015-05-21 | 2019-09-10 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as PAD4 inhibitors |
| AR108012A1 (es) * | 2016-03-31 | 2018-07-04 | Takeda Pharmaceuticals Co | Derivados de azaespiro[3,4]octan-6-ona como inhibidores de magl |
-
2019
- 2019-08-12 PE PE2020002021A patent/PE20211380A1/es unknown
- 2019-08-12 CR CR20210056A patent/CR20210056A/es unknown
- 2019-08-12 CN CN201980048654.2A patent/CN112469724A/zh active Pending
- 2019-08-12 KR KR1020217004224A patent/KR20210044217A/ko active Search and Examination
- 2019-08-12 BR BR112020025642-0A patent/BR112020025642A2/pt unknown
- 2019-08-12 EP EP19755856.2A patent/EP3837264A1/fr active Pending
- 2019-08-12 SG SG11202012222TA patent/SG11202012222TA/en unknown
- 2019-08-12 CA CA3098272A patent/CA3098272A1/fr active Pending
- 2019-08-12 MA MA053220A patent/MA53220A/fr unknown
- 2019-08-12 JP JP2021503816A patent/JP2021533093A/ja active Pending
- 2019-08-12 AU AU2019322161A patent/AU2019322161A1/en active Pending
- 2019-08-12 MX MX2020013719A patent/MX2020013719A/es unknown
- 2019-08-12 WO PCT/EP2019/071522 patent/WO2020035425A1/fr unknown
- 2019-08-13 TW TW108128684A patent/TWI814882B/zh active
- 2019-08-13 AR ARP190102302A patent/AR115949A1/es unknown
-
2021
- 2021-02-09 IL IL280762A patent/IL280762A/en unknown
- 2021-02-10 CL CL2021000361A patent/CL2021000361A1/es unknown
- 2021-02-11 PH PH12021500015A patent/PH12021500015A1/en unknown
- 2021-02-11 US US17/174,000 patent/US20210277020A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CR20210056A (es) | 2021-03-02 |
| TWI814882B (zh) | 2023-09-11 |
| EP3837264A1 (fr) | 2021-06-23 |
| AR115949A1 (es) | 2021-03-17 |
| TW202035421A (zh) | 2020-10-01 |
| PE20211380A1 (es) | 2021-07-27 |
| IL280762A (en) | 2021-04-29 |
| JP2021533093A (ja) | 2021-12-02 |
| PH12021500015A1 (en) | 2021-09-13 |
| CA3098272A1 (fr) | 2020-02-20 |
| BR112020025642A2 (pt) | 2021-03-23 |
| WO2020035425A1 (fr) | 2020-02-20 |
| KR20210044217A (ko) | 2021-04-22 |
| AU2019322161A1 (en) | 2020-11-12 |
| MA53220A (fr) | 2021-11-17 |
| CL2021000361A1 (es) | 2021-07-09 |
| MX2020013719A (es) | 2021-03-02 |
| CN112469724A (zh) | 2021-03-09 |
| US20210277020A1 (en) | 2021-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279173A (en) | Heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL280762A (en) | Heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
| FI3873903T3 (fi) | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina | |
| IL283333A (en) | Heterocyclic compounds | |
| IL290508A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL274762A (en) | Novel heterocyclic compounds as PRMT5 inhibitors | |
| EP4069212A4 (fr) | Inhibiteurs de hif-2 alpha | |
| IL289594A (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| IL289439A (en) | Heterocyclic compounds as bet inhibitors | |
| EP3906029A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| IL282659A (en) | Heterocyclic compounds as bet inhibitors | |
| IL287767A (en) | cdk inhibitors | |
| SG11202013016YA (en) | Heterocyclic compounds as trk inhibitors | |
| IL289617A (en) | Heterocyclic compounds | |
| IL289595A (en) | Heterocyclic compounds | |
| EP3609882A4 (fr) | Inhibiteurs hétérocycliques de pcsk9 | |
| IL288936A (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| EP3720495A4 (fr) | Composés hétérocycliques en tant qu'inhibiteurs de prmt5 | |
| IL289914A (en) | enzyme inhibitors | |
| IL288987A (en) | New heterocyclic compounds | |
| IL289389A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL289863A (en) | enzyme inhibitors | |
| IL289778A (en) | enzyme inhibitors | |
| IL289783A (en) | enzyme inhibitors |